Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with Calibrated Automated Thrombography

Thrombosis Research

Volumn 127, Issue 1, 2011, Pages 29-34

  Hacquard, Marie ^a,c,d   Perrin, Julien ^b,c,d   Lelievre, Nicolas ^a,c   Vigneron, Claude ^b,c,d   Lecompte, Thomas ^a,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Anticoagulant effect; Fondaparinux; Inter individual variability; Low molecular weight heparins; Thrombin generation

Indexed keywords

BEMIPARIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RO 14; THROMBIN; TINZAPARIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; CALIBRATED AUTOMATED THROMBOGRAPHY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INTERINDIVIDUAL VARIABILITY; NORMAL HUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE POOR PLASMA;

ANTICOAGULANTS; ANTITHROMBINS; AUTOMATION, LABORATORY; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CALIBRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, FLUORESCENCE; THROMBIN; TIME FACTORS;

EID: 78650511502     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.07.024     Document Type: Article

References (27)

1. L. Bara, and M. Samama Pharmacokinetics of low molecular weight heparins Acta Chir Scand 543 1988 65 72
2. J. Hirsh, K. Bauer, M. Donati, M. Gould, M.M. Samama, and J.I. Weitz Parenteral Anticoagulants. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 141S 159S (Pubitemid 351892966)
3. E. Gray, B. Mulloy, and T. Barrowcliffe Heparin and low molecular weight heparin Thromb Haemost 99 2008 807 818
4. M. Alhenc-Gelas, J. Le Guernic, J. Vitoux, A. Kher, M. Aiach, and J.N. Fiessinger Adjusted versus fixed doses of the low-molecular weight heparin Fragmin in the treatment of deep vein thrombosis Thromb Haemost 71 1994 698 702
5. R. Al Dieri, S. Alban, S. Béguin, and H.C. Hemker Fixed dosage of low- molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight J Thromb Haemost 4 2006 83 89
6. S. Robert, J. Ghiotto, B. Pirotte, J.L. David, B. Masereel, and L. Pochet Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res 59 2009 160 166
7. R. Al Dieri, S. Alban, S. Béguin, and H.C. Hemker Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time J Thromb Haemost 2 2004 1003 1007
8. S. Petros, T. Siegemund, A. Siegemund, and L. Engelmann The effects of different anticoagulants on thrombin generation Blood Coagul Fibrinolysis 17 2006 131 137
9. C. Cimenti, M. Koestenberger, B. Leschnik, H. Haidl, and W. Muntean The respective and combined anticoagulant effect of recombinant human activated protein C, melagatran and heparins using CAT Thromb Res 119 2006 361 367
10. G. Gerotziafas, A. Petropoulou, E. Verdy, M.M. Samama, and I. Elalamy Effect of the anti-factor Xa and anti-factor IIa activities of low- molecular-weight heparins upon the phases of thrombin generation J Thromb Haemost 5 2007 955 962
11. M.M. Samama, L. Le Flem, C. Guinet, G. Gerotziafas, and F. Depasse Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants J Thromb Haemost 5 2007 2554 2556
12. H.C. Hemker, P. Giesen, R. Al Dieri, V. Regnault, E. de Smedt, R. Wagenvoord, T. Lecompte, and S. Béguin Calibrated automated thrombin generation measurement in clotting plasma Pathophysiol Haemost Thromb 33 2003 4 15
13. Y. Dargaud, R. Luddington, E. Gray, C. Negrier, T. Lecompte, and S. Petros Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicenter study Br J Haematol 139 2007 303 309
14. E. Lindhoff-Last, G. Mosch, and H.K. Breddin Treatment doses of different low-molecular weight heparins and unfractionated heparins differ in their anticoagulating effects in respect to aptt, heptest, anti-iia-and anti-xa-activity Lab Med 16 1992 174 177
15. A. Leizorovicz, L. Bara, M.M. Samama, and M.C. Haugh Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurence of thrombosis and haemorrhage Haemostasis 23 1993 89 98
16. A. Smogorzewska, J. Brandt, W. Chandler, M.T. Cunningham, T.E. Hayes, and J.D. Olson Effect of Fondaparinux on Coagulation Assays. Results of College of American Pathologists Proficiency Testing Arch Pathol Lab Med 130 2006 1605 1611
17. S. Béguin, D. Welzel, R. Al Dieri, and H.C. Hemker Conjectures and Refutations on the Mode of Action of Heparins: The Limited Importance of Anti-Factor Xa Activity as a Pharmaceutical Mechanism and a Yardstick for Therapy Haemostasis 29 1999 170 178
18. J. Walenga, W.P. Jeske, L. Bara, M.M. Samama, and J. Fareed Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide Thromb Res 86 1997 1 36
19. Product characteristics, Arixtra®
20. J. Walenga, L. Bara, D. Hoppensteadt, J. Choay, J. Fareed, and M.M. Samama ATIII as a rate limiting factor for the measurement of pentasaccharide in laboratory assays Thromb Haemost 65 1991 1314
21. B. Boneu, J. Necciari, R. Cariou, P. Sié, A.M. Gabaig, and G. Kieffer Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man Thromb Haemost 74 1995 1468 1473
22. G. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M.M. Samama In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban J Thromb Haemost 5 2007 886 888
23. J.A. Anderson, J. Hirsh, S. Yusuf, M. Johnston, R. Afzal, and S.R. Mehta Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)-5 trial J Thromb Haemost 8 2010 243 249
24. A. Padilla, E. Gray, D.S. Pepper, and T. Barrowcliffe Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 Br J Haematol 82 1992 406 413
25. K.A. Bauer, D.W. Hawkins, P.C. Peters, M. Petitou, J.M. Herbert, and C.A. van Boeckel Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors Cardiovasc Drug Rev 20 2002 37 52 (Pubitemid 34657226)
26. A. McCoy, X.Y. Pei, R. Skinner, J.P. Abrahams, and R.W. Carrell Structure of β-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity J Mol Biol 326 2003 823 833
27. S. Butenas, C. van't Veer, and K. Mann "Normal" Thrombin Generation Blood 94 1999 2169 2178